Ono Entered into an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies
- Monash University to receive up front along with the research funding during the option period & is also eligible to receive milestones along with royalties based on future net sales if Ono exercises its option
- Monash University’s Biomedicine Discovery Institute will be responsible for the Ab discovery campaign to target two GPCRs traditionally hard to target. Ono to get an exclusive right globally to develop and commercialize existing Abs
- The collaboration combines Monash University’s expertise in anti-GPCR Ab discovery with Ono’s exceptional capabilities in drug development to develop Abs targeting GPCRs for novel therapies in autoimmune and inflammatory diseases
Ref: Ono | Image: Ono
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.